Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.